Lexicon Pharmaceuticals Inc Stock Price, News & Analysis

Lexicon Pharmaceuticals announced that their Phase 2 RELIEF-DPN-1 clinical trial results for LX9211, an investigational non-opioid therapy for diabetic peripheral neuropathic pain (DPNP), were published in Diabetes Care. The study, conducted over 11 weeks, showed that LX9211 significantly reduced average daily pain scores in the low-dose group and was well tolerated by patients. The successful outcomes support the commencement of the Phase 2b PROGRESS trial, which is currently enrolling patients in the U.S.

Existing DPNP treatments often provide only modest pain relief and come with significant side effects. LX9211's promising results indicate it may offer a more effective and safer alternative for DPNP sufferers.

Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced that a new analysis published in the Journal of the American College of Cardiology: Heart Failure concludes that INPEFA® (sotagliflozin) is cost-effective for patients with diabetes and recent worsening heart failure. The peer-reviewed study, conducted from a U.S. healthcare perspective, follows Consolidated Health Economic Evaluation Reporting Standards. It reveals that lifetime quality-adjusted life-years (QALYs) were higher for the INPEFA group (4.43) compared to the placebo group (4.04), confirming the drug's economic viability. Another study in the Journal of Comparative Effectiveness Research supports these findings, showing a net QALY gain of 0.425 for INPEFA. Lexicon's senior VP, Craig Granowitz, emphasized the financial and clinical benefits for the U.S. healthcare system.

Lexicon Pharmaceuticals announces three poster presentations at the 84th Scientific Sessions of the American Diabetes Association from June 21-24, 2024, in Orlando, Florida. The presentations will occur on June 23, from 12:30 - 1:30 p.m. ET, focusing on diabetic peripheral neuropathic pain (DPNP) and the efficacy of sotagliflozin. The studies include patient-reported burdens of DPNP, the impact of sotagliflozin as an add-on for inadequately controlled basal insulin-treated type 2 diabetes, and a comparison of sotagliflozin vs. empagliflozin or placebo in type 2 diabetes. This research underscores Lexicon's efforts to address unmet medical needs in diabetes.

Lexicon Pharmaceuticals (Nasdaq: LXRX) announced its participation in the Jefferies Global Healthcare Conference on June 5, 2024. Jeff Wade, president and CFO, along with Craig Granowitz, senior VP and chief medical officer, will join a moderated discussion at 3:00 pm ET. A live webcast will be available on Lexicon's website, with a recording accessible for two weeks post-event.

Lexicon Pharmaceuticals announced a new post-hoc analysis of pooled Phase 3 data showing that INPEFA® (sotagliflozin), a dual oral inhibitor of SGLT2 and SGLT1, significantly reduced the risk of heart failure events in patients with preserved ejection fraction (HFpEF). The analysis, presented at the Heart Failure Association of the European Society of Cardiology Congress, highlighted INPEFA's effectiveness in patients with obesity-related HFpEF. Data from the SOLOIST-WHF and SCORED trials involving 1,932 patients indicated that age, sex, and BMI were important risk factors. Notably, older patients and those with higher BMI saw a greater reduction in primary endpoint events with INPEFA compared to placebo. The findings emphasize the need for personalized treatment strategies for HFpEF patients.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will participate in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon’s president and chief financial officer, will present on May 14, 2024. A webcast will be available on the Lexicon website.

Lexicon Pharmaceuticals reported financial results for the first quarter of 2024, highlighting the progress in the commercial launch of INPEFA for heart failure. They also provided updates on the resubmission of NDA for ZYNQUISTA in Type 1 Diabetes, Phase 3 study of sotagliflozin in Hypertrophic Cardiomyopathy, and Phase 2b PROGRESS study of LX9211 in Diabetic Peripheral Neuropathic Pain. The company remains focused on advancing its pipeline with the selection of LX9851 for obesity and weight management. Financially, the company reported revenues of $1.1 million, with increased R&D and SG&A expenses resulting in a net loss of $48.4 million for the quarter. Lexicon Pharmaceuticals remains well-capitalized with $355.6 million in cash and investments.

Lexicon Pharmaceuticals, Inc. announced the retirement of Lonnel Coats as CEO and board member effective July 7, 2024. The board is searching for a new CEO. Under Coats' leadership, Lexicon has advanced compounds through development, transformed into a biopharmaceutical business, and built a strong management team. Coats expressed gratitude for the opportunity to lead the company and highlighted upcoming initiatives, including the launch of new products and clinical studies.